Stockreport

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc.  (SPRB) 
PDF Granted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfillipo Syndrome Type B (MPS IIIB)Biologics L [Read more]